PCK1 and SLC22A2 gene variants associated with response to metformin treatment in type 2 diabetes.

ABSTRACT: Type 2 diabetes (T2D) is a chronic disorder affecting 462 million worldwide, often managed with metformin as first-line treatment. However, metformin's response varies among individuals, including up to 30% experiencing serious adverse drug reactions (ADRs) and 20-50% inefficacy. These differences may be due to various factors, including pharmacogenetic (PGx) variants. The PGx variants documented so far could affect both the safety and efficacy of metformin, but due to a lack of replication studies, none reached the clinical evidence-level needed to be used as a predictive marker for treatment response. Therefore, this study aims to evaluate the association between the presence of candidate PGx variants and metformin response in T2D subjects. We conducted an association study involving 108

SUBMITTER: St-Amour S 

PROVIDER: S-EPMC11809887 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature